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ABSTRACT
The synthesis of novel derivatives of pyrazole-3-carboxylate (3–5) from methyl 4-(benzofuran-2-yl)-2,4-dioxobutanoate (1) is
reported. Synthesis of substituted 1,3,4-oxadiazoles (7–11) and 5-amino pyrazole-4-carboxylate (12) derivatives starting from the
5-(benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-carbohydrazide (6) are also described. Twelve new compounds were synthesized
and their identities have been established on the basis of elemental and spectroscopic analysis such as IR, 1H NMR, 13C NMR,
Mass Spectra. The compounds were also screened for their antibacterial and antifungal activities against Gram-positive, Gram-
negative bacteria and a fungus.
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1. Introduction
2,4-Dioxobutanoate derivatives have been found to be very
reactive towards organic reagents such as hydroxyl amine
hydrochloride, semicarbazide hydrochloride, hydrazine
hydrate and phenyl hydrazine, hence they are utilized for the
synthesis of substituted isoxazoles and pyrazole carboxylates.
Compounds having a pyrazole nucleus are known to possess
some important pharmacological activities such as antitumor,1–4
antibacterial,5 fungicidal,6,7 antidiuretic,8 anticancer,9 potent
antidiabetic agent,10 anti-inflammatory,11 antidepressant,12,13 and
antiviral14 activities. Some substituted pyrazoles are cycloxy-
genes-2-(Cox2) selective inhibitors.15 A literature survey indi-
cated that pyrazole carboxylates when reacted with hydrazine
hydrate yield pyrazole carbohydrazides16,17 possessing interest-
ing bioactivities such as antifungal18,19, antimalarial,20 anti-
convulsant,21 antituberculosis22,23 and anticancer.24
Pyrazole carbohydrazide reacts with different reagents to give
1,3,4-oxadiazoles which have a broad spectrum of biological
and industrial activities.25,26 Among the biological applications
reported for 1,3,4-oxadiazoles are hypnotic,27 anticancer,28 anti
tuberculostatic,29 antimalarial,30 antimicrobial,31,32 antiviral,33,34
hypoglycaemic,35 anti-HIV activity,36 insecticidal,37 and anti-
fungal38 activities. In view of these reports and in continuation of
our previous work39 we describe here a facile synthesis of
isoxazole and pyrazole-3-carboxylates from methyl 4-(benzo-
furan-2-yl)-2,4-dioxobutanoate 1. Simultaneously, we have
extended the reactions of 5-(benzofuran-2-yl)-1-phenyl-1H-
pyrazole-3-carbohydrazide 6 with different reagents to afford
new 1,3,4-oxadiazoles and 5-amino pyrazole-4-carboxylate
derivatives by adapting previously reported procedures.17
2. Results and Discussion
The syntheses of the title compounds 1–12 are described in
Schemes 1 and 2. At every stage the reaction was monitored
with TLC. The identities of these synthesized compounds have
been established on the basis of elemental analysis and spectral
data such as IR, 1H NMR, 13C NMR and Mass Spectra and they
were also screened for their antimicrobial activities. The synthe-
sis of the start ing compound, methyl 4-(benzo-
furan-2-yl)-2,4-dioxobutanoate 1 achieved in quantitative yields
by the reference method.39 The IR spectrum of 1 showed the
enolic –OH stretch at 3475 cm–1 and C=O stretching in ester
group at 1759 cm–1. The 1H NMR spectrum showed a singlet39 at
d 14.24 ppm due to –OH proton, singlet at d 3.95 ppm due to
OCH3, multiplet at d 7.27–7.72 ppm due to aromatic protons and
singlet at d 7.10 ppm confirms vinylic =CH proton. A chemical
shift value in 13C NMR is observed at d 53.3 ppm due to methoxy
carbon; the carbon atoms connected to methoxy group are
observed at the range of d 156–167 ppm, signal at d 167.9 ppm is
due to C-1 carbon in C=O of the ester group whereas C-4 carbon
in C=O group under the influence of strong electronegative
environment appears downfield at d 181.0 ppm; the aromatic
carbons were observed in expected region. The mass spectrum
of this product reveals a molecular ion at m/z 247 [M+H]+ is in
consistent with the molecular formula C13H10O5.
Methyl 4-(benzofuran-2-yl)-2,4-dioxobutanoate 1 on reaction
with hydroxyl amine hydrochloride and sodium acetate in abso-
lute ethanol gave methyl 4-(benzofuran-2-yl)-2-(hydroxy-
imino)-4-oxobutanoate 2a. The 1H NMR spectrum showed a
singlet at d 12.39 ppm corresponding to enolic -OH proton,
multiplet a d 7.20–7.73 due to aromatic protons, this confirmed
that cyclization has not occurred to form an isoxazole ring.
Hence, 2a was heated in 50 mL absolute ethanol in presence of
conc. HCl for 2 hours to get methyl 5(benzofuran-2-yl)-isoxa-
zole-3-carboxylate 2, where a multiplet at d 7.23–7.75 ppm due to
aromatic protons, and a quartet at d 4.41–4.46, a triplet at
d 1.39–1.42 ppm due to the presence of the COOCH2CH3 group
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confirmed that trans esterification has also occurred simulta-
neously.
Treatment of 1 with semicarbazide hydrochloride and sodium
acetate in absolute ethanol gave 3, with hydrazine hydrate in
acetic acid afforded 4, while its reaction with phenyl hydrazine
in acetic acid furnished 5.
Formulation of the reaction products designated 2, 3, 4 and 5
in Scheme 1, was based upon the comparative reactivity of two
carbonyl groups in 1. The C-2 carbonyl group being more
reactive than the C-4 carbonyl group, the first gets preferably
attacked by the nucleophilic reagent such as hydroxylamine
hydrochloride, semicarbazide hydrochloride, hydrazine hydrate
and phenyl hydrazine to give the corresponding intermediate
which simultaneously undergo ring closure with elimination of
a water molecule from the imino proton and the –OH group of
the enolized C-4carbonyl group forming 2, 3, 4 and 5. The reaction
of 5 with hydrazine hydrate in ethanol gave 5-(benzofuran-
2-yl)-1-phenyl-1H-pyrazole-3-carbohydrazide 6. The character-
istic IR bands in compounds 3, 4, 5 and 6 at 1694, 1693 1618 and
1649 cm–1, respectively shows strong stretching bands due to the
C=N group in pyrazole ring.
5-(benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-carbohydrazide
6 was further utilized for the synthesis of several innovative
azoles 7–12. The interaction of 6 with carbon disulphide in
pyridine gave 7. The IR spectra of 7 showed a characteristic
absorption band at 3405 cm–1 due to NH; similarly, 1H NMR
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revealed an exchangeable imino proton at d 14.79 ppm due to
–NH in oxadiazole ring and absence of SH signal indicates its
existence as the thione tautomer. The thione function of 7 was
alkylated using the bioactive alkylating agent 4-(2-chloroethyl)
morpholine hydrochloride in absolute ethanol (99.9 %) in
presence of fused sodium acetate to afford 4-(2-(5-(5-(benzo-
furan-2-yl)-1-phenyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-ylthio)
ethyl) morpholine 8. The 1H NMR spectrum of 8 showed a
singlet at d 6.28 ppm due to CH in pyrazole and a multiplet at
d 7.20–7.55 ppm due to aromatic protons; similarly, a singlet at
d 2.58 ppm due to –CH2NCH2, a singlet at d 2.88 ppm due to
–SCH2CH2N, a singlet at d 3.53 ppm due to –SCH2CH2N, and a
singlet at d 3.74 ppm due to –CH2OCH2. In the
13C NMR spec-
trum the C-2 and C-5 carbon of the oxadiazole gave signals
at 164.40 and 159.95 ppm. The mass spectrum of compound 8
displayed a molecular ion peak at m/z 474 [M+H]+ which is in
agreement with the molecular formula C25H23O3N5S.
Treatment of the 6 with N,N’-carbonyldiimidazole (CDI) in
dioxane gave 9. The IR spectra of 9 showed a characteristic
absorption band at 1768 cm–1 due to C=O. The 1HNMR spectrum
showed a singlet at d 12.38 ppm due to NH of oxadiazole. The
reaction of 6 with acetyl chloride in dioxane did not afford the
expected product 10. However, the N-acetyl carboxylic acid
hydrazide was shown to be the reaction product. The formation
of N’-acetyl-5-(benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-
carbohydrazide 10a as an intermediate was confirmed from the
1H NMR spectra. A singlet at d 1.98 ppm due to CH3, one singlet
at d 10.11 ppm and another singlet at d 10.55 ppm due to the NH
protons, a multiplet at d 7.22–8.08 ppm due to aromatic protons,
revealed that cyclization did not occur to give 10. Therefore,
10a was subjected to cyclodehydration in phosphorous oxy-
chloride to give the corresponding oxadiazole 10, which was also
obtained by heating 6 with acetic acid in POCl3. Similarly,
another oxadiazole derivative 11 was obtained by the reaction
of 6 with benzoic acid in POCl3. The IR absorption bands in
the range of 1695–1600 cm–1 is due to C=N group and bands
observed in the range of 1275–1200 and 1075–1020 cm–1 are
due to C-O-C grouping of 1,3,4-oxadiazole nucleus of the com-
pounds 7–11.
Finally, the reaction of 6 with ethyl(ethoxymethylene) cyano-
acetate in ethanol gave the corresponding ethyl 5-amino-
1-(5-(benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-carbonyl)-
1H-pyrazole-4-carboxylate 12. The IR spectra of 12 showed a
characteristic absorption band at 1697 cm–1 due to C=O stretch.
The 1H NMR spectrum showed a triplet at d 1.32–1.35 ppm for
–CH2CH3and quartet at d 4.25–4.30 ppm for –CH2CH3, singlet at d
6.3 ppm due to CH in pyrazole and multiplet at d 7.23–7.63 ppm
for thirteen protons including 11 aromatic and two NH2 protons.
Its mass spectrum gave a molecular ion at m/z 442[M+H]+ and
elemental analysis showed that it is consistent with the molecu-
lar formula C24H19O4N5.
Carbon atoms in all the novel synthesized compounds 1–12
from the 13C NMR spectra were seen at their expected chemical
shifts; similarly, their mass spectrum revealed a molecular ion
peak at m/z [M+H]+ which are in agreement with the molecular
formulae of all these synthesized compounds. It was found that
the spectral data such as IR, 1H NMR, 13C NMR, and Mass spec-
trum of all these newly synthesized compounds in Schemes 1
and 2 were in accordance with the proposed structures.
MIC values are in the range of 15.5–500 µg mL–1 for both Gram-
positive and Gram-negative bacteria was observed (see Table 1).
The title compounds were graded as highly active with
MIC values of 15.5–62 µg mL–1, moderately active at 125 µg mL–1
and poorly active at values 250–500 µg mL–1. The antibacterial
screening results revealed that most of the synthesized com-
pounds 1–12, exhibited significant antibacterial activities. The
test compounds 1, 7, 8 and 12 were found to be highly active,
while 2, 5, 10 and 11 were moderately active against B. subtilis.
Compounds 4, 5, 8, 10 and 11 were highly active, while 1 and 3
were moderately active against S. aureus. 4, 6, 8 and 10 were
highly active but 2, 7 and 12 were moderately active against
E. coli. Compound 5 has shown excellent antibacterial activity as
compared to the standard drug against E. coli. Compounds 2, 10,
11 and 12 were highly active while 1, 4, 6 and 9 were moderately
active against P. aeruginosa. However, all these compounds
exhibited significant activity in the range of 31 250 µg mL–1
against A. niger, compounds 1, 2, 3, 6, 10 and 12 were found to be
highly active while 5, 8 and 11 are moderately active. The rests of
the compounds gave poor activities against all the test bacteria
and a fungus.
3. Experimental
Melting points were recorded in open capillary in silicon oil
bath and are uncorrected. IR spectra were recorded on a
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Table 1. Antibacterial activity of compounds 1–12
Compound no. Minimum inhibitory concentration (MIC/µg mL–1)
B. subtilis S. aureus E. coli P. aeruginosa A. niger
(NCIM 2439) (NCIM 2079) (NCIM 2064) (NCIM 2053) (NCIM 501)
1 62 125 250 125 62
2 125 250 125 62 31
3 500 125 250 250 25
4 250 62 31 125 250
5 125 15.5 15.5 500 125
6 250 500 62 125 12.5
7 31 250 125 500 250
8 31 62 62 250 12.5
9 250 250 500 125 250
10 125 31 62 62 62
11 125 31 250 62 125
12 62 250 125 31 62
Ampicillin 25 12.5 25 25 –
Clotrimazole – – – – 12.5
DMSO – – – – –
MIC: Lowest concentration of an antimicrobial agent that significantly inhibits the visible growth of microorganism after a period of incubation.
Shimadzu IR Spectrophotometer in KBr pellets. 1H NMR and
13C NMR spectra are recorded on a Bruker AM 400 instrument
(400 MHz) using tetramethylsilane (TMS) as an internal refer-
ence and DMSO-d6/CDCl3 as solvent. Chemical shifts are given
in parts per million (ppm). Positive-ion electrospray ionisation
(ESI) mass spectra were obtained with a Waters Micromass
Q–TOF Micro, Mass Spectrophotometer. Elemental analysis
was done using Vario EL III Elemental Analyzer, all compounds
showed satisfactory elemental analysis. The reaction was moni-
tored by E. Merck TLC aluminum sheet silica gel60F254 and visual-
izing the spot in UV light and iodine chamber.
Synthesis of Methyl 4-(Benzofuran2-yl)-2,4-dioxobutanoate (1)
Diethyloxalate (1.46 mL, 10 mmol) was gradually added with
stirring to a solution of 2-acetyl benzofuran (1.6 g, 10 mmol) and
sodium methoxide (0.23 g Na in 5 mL methanol, 10 mmol) in
N,N-Dimethylformamide (100 mL). The reaction mixture was
stirred for 12 h at room temperature, the product obtained was
acidified by 1:1 ice-cold HCl, filtered, washed with water and
recrystallized from acetone to get yellow crystalline solid 1
(85 %); m.p.: 131–133 °C; Rf = 0.66 (ethylacetate/n-hexane 1:2); IR
(KBr, nmax): 3475 (-OH), 3059, 3020 (ArH), 2968, 2879 (CH3) 1805,
1759 (C=O, ester), 1624, 1573, 1521 (C=C) cm–1; 1H NMR (CDCl3):
d 3.95 (s, 3H, CH3), 7.10 (s, 1H, =CH), 7.27–7.72 (m, 5H, ArH),
14.24 (s, 1H, –OH) ppm; 13C NMR (CDCl3): 53.3, 99.3, 112.4, 114.1,
123.3, 124.2, 127.3, 128.8 , 150.8, 156.2, 162.3, 167.9, 181.0 ppm;
ESI(+)-MS: m/z 247 (M+H)+. Anal. calcd. for C13H10O5: C, 63.41;
H, 4.06 %. Found: C, 62.52; H, 4.13 %.
Synthesis of Methyl 5-(Benzofuran-2-yl)-isoxazole-3-
carboxylate (2)
Hydroxylamine hydrochloride (1.39 g, 20 mmol) and sodium
acetate (1.64 g, 20 mmol) were added to a mixture of methyl
4-(benzofuran-2-yl)-2,4-dioxobutanoate 1 (2.46 g, 10 mmol) in
absolute ethanol (99.9 %, 200 mL), and the reaction mixture was
refluxed for 4 h. It was concentrated, cooled, poured in ice-cold
water and kept overnight; the solid separated out was filtered
and recrystallized from diluted ethanol to get 2a, as an interme-
diate. Further, 2a was refluxed for 2 h in absolute ethanol (50 mL)
and conc. HCl (1 mL). The solvent was evaporated under
reduced pressure to get pale yellow crystalline solid 2 (90 %);
recrystallized from ethanol; m.p.: 80–82 °C; R f = 0.62
(ethylacetate/n-hexane 1:2); IR (KBr, nmax): 3084 (ArH), 2991, 2943
(CH3), 1723 (C=O, ester), 1620 (C=N), 1546, 1477, 1459, 1435
(C=C) cm–1; 1H NMR (DMSO-d6): d 1.39–1.42 (t, J = 8 Hz,
3H,-OCH2CH3), 4.41–4.46 (q, J = 8 Hz, 2H, -OCH2 CH3), 7.23–7.75
(m, 6H, ArH) ppm; 13C NMR (DMSO-d6): d 13.8, 61.8, 101.5, 107.1,
111.4, 122.1, 123.7, 126.5, 127.3, 142.7, 154.7, 156.4, 158.7,
162.4 ppm; ESI(+)-MS: m/z (%) 258 (M+H)+; Anal. calcd. for
C14H11O4N: C, 65.36; H, 4.28; N, 5.45 %. Found: C, 65.03; H, 4.01;
N, 5.39 %.
Synthesis of Methyl 5-(Benzofuran-2-yl)-1-carbamoyl-1H-
pyrazole-3-carboxylate (3)
Semicarbazide hydrochloride (1.12 g, 10 mmol) and sodium
acetate (0.82 g, 10 mmol) were added to methyl 4-(benzo-
furan-2-yl)-2,4-dioxobutanoate 1 (1.23 g, 5 mmol) in absolute
ethanol (99.9 %, 10 mL), and the reaction mixture was refluxed
for 4 h. It was then concentrated, cooled and poured in ice-cold
water, solid separated out was filtered and recrystallized from
ethanol to get white crystalline solid 3 (76 %); m.p.: 142–144 °C;
Rf = 0.61 (ethylacetate/n-hexane 1:2); IR (KBr, nmax): 3461, 3405,
3255, 3165 (NH2), 3052, 3011 (ArH), 2956, 2919, 2853 (CH3), 1769,
1744 (C=O, ester), 1694 (C=N), 1589 (C=N), 1395 (C-N, amide),
1500, 1436, 1408 (C=C) cm–1; 1H NMR (DMSO-d6): d 3.95 (s,
3H,-COOCH3), 7.23–7.91 (m, 8H, Ph + NH2) ppm;
13C NMR
(DMSO-d6): d 51.7, 109.1, 111.4, 121.8, 123.1, 125.5, 128.1, 136.1,
143.4, 144.4, 150.2, 154.0, 154.1, 161.0 ppm; ESI(+)-MS: m/z ( %)
286 (M+H)+; Anal. calcd. for C14H11O4N3: C, 58.94; H, 3.85; N,
14.73 %. Found: C, 58.88; H, 3.68; N, 14.54 %.
Synthesis of Methyl 5-(Benzofuran-2-yl)-1H-pyrazole-
3-carboxylate (4)
Hydrazine hydrate (1.5 mL, 30 mmol) was added gradually
with constant stirring to methyl 4-(benzofuran-2-yl)-2,4-dioxo-
butanoate 1 (2.46 g, 10 mmol) in CH3COOH (30 mL), and
refluxed for 2 h. After that it was poured in ice-cold water, filtered
and recrystallized from ethanol to get white crystalline solid 4
(90 %); m.p.: 180–182 °C; Rf = 0.65 (ethylacetate/n-hexane 1:2); IR
(KBr, nmax): 3254, 3165 (NH), 3051, 3011 (ArH), 2957 (CH3), 3876
(C=O), 1693 (C=N), 1492, 1453, 1436, (C=C) cm–1; 1H NMR
(DMSO-d6): d 3.91 (s, 3H,-COOCH3), 7.15–7.62 (m, 7H, ArH +
NH) ppm; 13C NMR (DMSO-d6): d 51.53, 102.39, 105.62, 110.77,
120.91, 122.94, 124.35, 128.08, 132.08, 133.09, 141.46, 153.96,
167.28 ppm; ESI(+)-MS: m/z 243 (M +H)+; Anal. calcd. for
C13H10O3N2: C, 64.46; H, 4.13; N, 11.57 %. Found: C, 64.21; H, 4.34;
N, 11.77 %.
Synthesis of Methyl 5-(Benzofuran-2-yl)-1-phenyl-1H-
pyrazole-3-carboxylate (5)
Phenyl hydrazine (1.62 mL, 15 mmol) was added to a mixture
of methyl 4-(benzofuran-2-yl)-2,4-dioxobutanoate 1 (2.46 g,
10 mmol) in CH3COOH (30 mL), and the reaction mixture was
refluxed for 4 h. After that it was concentrated and poured in
crushed ice, filtered off and recrystallized from acetic acid as
white crystalline solid 5 (85 %); m.p: 161–163 °C; Rf = 0.63
(ethylacetate/n-hexane 1:2); IR (KBr, nmax): 3061 (ArH), 2955
(CH3), 1618 (C=N), 1734 (C=O, ester), 1593, 1500, 1436, 1408
(C=C) cm–1; 1H NMR (CDCl3) d: 3.97 (s, 3H, -COOCH3), 6.22 (s,
1H, pyrazole CH), 7.17–7.54 (m, 10H, ArH) ppm; 13C NMR
(CDCl3): d 52.30, 105.62, 109.41, 111.33, 121.44, 123.39, 125.48,
126.40 (2C), 127.93, 129.37 (2C), 129.72, 136.04, 139.53, 144.22,
145.06, 154.48, 162.45 ppm; ESI(+)-MS: m/z 319 (M+H)+; Anal.
calcd. for C19H14O3N2: C, 71.69; H, 4.40; N, 8.81 %. Found: C, 71.05;
H, 4.42; N, 8.42 %.
Synthesis of 5-(Benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-
carbohydrazide (6)
Hydrazine hydrate (100 %, 1.7 mL) was added to a mixture of
methyl 5-(benzofuran-2-yl)-1-phenyl-1H-pyrazole-3-car-
boxylate 5 (3.18 g, 10 mmol) in absolute ethanol (99.9 %, 100 mL),
and refluxed for 8 h. It was then concentrated, filtered and
recrystallized from ethanol as white crystalline solid 6 (88 %);
m.p: 145–146 °C; Rf = 0.61 (ethylacetate/n-hexane 1:2); IR (KBr,
nmax): 3429, 3317, 3225, 3159 (-NH.-NH2), 3066 (ArH), 1683 (C=O),
1649 (C=N), 1531, 1597 (C=C) cm–1; 1H NMR (CDCl3): d:
3.69–3.71 (s, 2H, -CONHNH2), 6.22 (s, 1H, pyrazole CH),
7.17–7.54 (m, 10H, ArH), 8.49 (b, 1H,-CONHNH2) ppm;
13C NMR
(CDCl3): d 105.68, 107.83, 111.38, 121.40, 123.37, 125.43, 126.05
(2C), 127.92, 129.43 (2C), 129.56, 136.04, 139.54, 145.15, 145.87,
154.51, 162.35 ppm; ESI (+)-MS: m/z 319 (M+H)+; Anal. calcd. for




A mixture of 6 (3.18 g, 10 mmol) in CS2 (30 mL) and pyridine
(100 mL) was refluxed on water bath for 6 h. Then it was cooled
and excess of solvent was removed under reduced pressure. The
residue obtained was triturated with ice-water mixture and
neutralized with dilute HCl. The solid obtained was filtered and
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recrystallized from ethanol to get white crystalline solid 7 (95 %);
m.p.: 249–250 °C; Rf = 0.61 (ethylacetate/n-hexane 1:2); IR (KBr,
nmax): 3405 (-NH), 3070, 3019 (ArH), 1636 (C=N-N=C), 1594, 1518,
1497, 1472, 1431 (C=C), 1255, 1072 (C-O-C), 1230 (C=S) cm–1;
1H NMR (DMSO-d6): d 6.5 (s, 1H pyrazole CH), 7.22–7.62 (m,
10H, ArH), 14.79 (s, 1H, -NH) ppm; 13C NMR (DMSO-d6):
d 105.99, 106.33, 110.91, 121.41, 123.24, 125.41, 125.68 (2C), 127.35,
129.23 (2C), 129.58, 135.77, 136.75, 138.83, 144.02, 153.92, 155.53,
177.34 ppm; ESI(+)-MS: m/z 361 (M+H)+; Anal. calcd. for C19 H12
O2 N4S: C, 63.33; H, 3.33; N, 15.55; S, 8.88 %. Found: C, 63.42; H,
3.30; N, 15.61; S, 8.94 %.
Synthesis of 4-(2-(5-(5-(Benzofuran-2-yl)-1-phenyl-1H-
pyrazol-3-yl)-1,3,4-oxadiazol-2-ylthio)ethyl) Morpholine (8)
A mixture of 7 (3.6 g, 10 mmol), sodium acetate (4.1 g, 50 mmol)
and morpholine hydrochloride (1.88 g, 10 mmol) in absolute
ethanol (99.9 %, 100 mL) was refluxed for 6 h. Then it was cooled,
excess of solvent was evaporated under reduced pressure; the
residue obtained was triturated with water. Solid obtained was
filtered off, recrystallized from ethanol as white crystalline solid
8 (89 %); m.p.: 160–162 °C; Rf = 0.56 (ethylacetate/n-hexane 1:2);
IR (KBr, nmax): 3030 (ArH), 1607 (C=N), 1593, 1555, 1518, 1514
(C=C) cm–1; 1H NMR (DMSO-d6): d 2.58 (s, 4H, -CH2NCH2-), 2.88
(s, 2H, SCH2CH2N), 3.53 (s, 2H, -SCH2CH2N), 3.74 (s, 4H,
-CH2OCH2-), 6.28 (s, 1H, pyrazole CH), 7.20–7.55 (m, 10H,
ArH) ppm; 13C NMR (DMSO-d6): d 29.89, 52.79 (2C), 56.60, 66.11
(2C), 105.95, 106.55, 110.95, 121.47, 123.29, 125.44, 125.78 (2C),
127.40, 129.28 (2C), 129.58, 135.69, 137.42, 138.92, 144.01, 153.91,
159.95, 164.40 ppm; ESI(+)-MS: m/z 474 (M+H)+; Anal. calcd. for
C25H23O3N5S: C, 63.42; H, 4.86; N, 14.79; S, 6.76. % Found: C, 63.41;
H, 4.42; N, 14.88; S, 6.96 %
Synthesis of 5-(5-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-
3-yl)-1,3,4-oxadiazol-2(3H)-one (9)
A mixture of 6 (3.18 g, 10 mmol) and N,N’-carbonyldiimidazole
(2.43 g, 15 mmol) in 1,4 dioxane (100 mL) was refluxed for 8 h. The
reaction mixture was cooled; residue obtained was triturated
with ice-water mixture. The solid obtained was filtered off,
recrystallized from ethanol as white crystalline solid 9 (70 %);
m.p.: 250–252 °C; Rf = 0.53 (ethylacetate/n-hexane 1:2); IR (KBr,
nmax): 3511, 3219, 3153 (-NH), 3115 (ArH), 1768 (C=O), 1627
(C=N), 1594, 1499, 1440 (C=C); 1H NMR (DMSO-d6): d 6.32 (s,
1H, pyrazole, CH), 7.20–7.69 (m, 10H, ArH), 12.38 (s, 1H,
NH) ppm; 13C NMR (DMSO-d6): d 105.74, 105.94, 110.96, 121.48,
123.30, 125.42, 125.75 (2C), 127.41, 129.27 (2C), 129.48, 135.43,
138.17, 138.98, 144.25, 149.29, 153.90, 154.06 ppm; ESI(+)-MS: m/z
345[(M+H)+, 100]; Anal. calcd. for C19H12O3N4: C, 66.27; H, 3.48;
N, 16.28 %. Found: C, 66.08; H, 3.51; N, 16.04 %
Synthesis of 2-(5-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-
3-yl)-5-phenyl-1,3,4-oxadiazole (10)
Method 1: Step I: Synthesis of N’-acetyl-5-(benzofuran-2-
yl)-1-phenyl-1H-pyrazole-3-carbohydrazide (10a): A mixture of 6
(3.18 g, 10 mmol) and acetyl chloride (1.18 mL, 15 mmol) in 1,4
dioxane (100 mL) was refluxed for 4 h. The reaction mixture
was concentrated, filtered and recrystallized from ethanol to
get white crystalline solid 10a (79 %); m.p.: 215–217 °C;
1H NMR (DMSO-d6): d 1.98 (s, 3H, CH3), 6.38 (s, 1H pyrazole
–CH), 7.22–8.08 (m, 10H, ArH), 10.11 (s, 1H, NH), 10.55 (s, 1H,
NH) ppm.
Step II: Synthesis of (10): The intermediate 10a obtained was
then refluxed in (25 mL) phosphorous oxychloride at 100 °C for
5 h. Then it was poured in ice-cold water and neutralized with
20 % NH4OH, filtered and recrystallized from ethanol as white
crystalline solid 10 (70 %); m.p.: 208–210 °C.
Method 2: Synthesis of (10): A mixture of 6 (1.27 g, 4 mmol) and
acetic acid (0.24 mL, 4 mmol) in POCl3, (40 mL) was refluxed for
2 h. Excess of solvent was evaporated under reduced pressure,
poured in water and neutralized with NH4OH. The solid
obtained was filtered off, and recrystallized from ethanol as
white crystalline solid 10 (80 %); m.p.: 208–210 °C; Rf = 0.59
(ethylacetate/n-hexane 1:2); IR (KBr, nmax): 3059 (ArH), 2974, 2927
(CH3), 1612, 1594, 1576, 1510, 1441, 1459 (C=C);
1H NMR
(DMSO-d6): d 2.61 (s, 3H, -CH3), 6.56 (s, 1H, pyrazole –CH),
7.22–7.62 (m, 10H, ArH) ppm; 13C NMR (DMSO-d6): d 10.53,
105.87, 106.54, 110.93, 121.41, 123.24, 125.38, 125.74 (2C), 127.40,
129.23 (2C), 129.50, 135.63, 137.81, 138.96, 144.23, 153.91, 159.61,
163.31 ppm; ESI(+)-MS: m/z 343 (M+H)+; Anal. calcd. for C20 H14




A mixture of 6 (3.18 g, 10 mmol) and benzoic acid (1.22 g,
10 mmol) in POCl3 (15 mL) was refluxed on steam bath for 6 h.
The reaction mixture was cooled and poured on ice-water; Ph of
the solution was maintained to 7 by adding NH3. The solid
obtained was filtered off and recrystallized from 1,4 dioxane as
white crystalline solid 11 (95 %); m.p.: 250–252 °C; Rf = 0.58
(ethylacetate/n-hexane 1:2); IR (KBr, nmax): 3065 (ArH), 1694
(C=N), 1591, 1549, 1461, 1493, 1445 (C=C), 1259 (C-O-C);
1H NMR (DMSO-d6): d 6.50 (s, 1H, pyrazole CH), 7.22–8.18 (m,
15H, ArH) ppm; ESI(+)-MS: m/z 405 (M+H)+; Anal. calcd. for
C25H16O2N4: C, 74.25; H, 3.96; N, 13.86 %. Found: C, 74.18; H, 4.02;
N, 14.12 %
Synthesis of Ethyl 5-Amino-1-(5-(benzofuran-2-yl)-1-phenyl-
1H-pyrazole-3-carbonyl)-1H-pyrazole-4-carboxylate (12)
A mixture of 6 (3.18 g, 10 mmol) and ethylethoxymethylene
cyanoacetate (1.69 g, 10 mmol) in absolute ethanol (99.9 %,
100 mL) was refluxed for 8 h. After cooling the solvent was
removed in vacuo, filtered and recrystallized from ethanol as
fluffy white solid 8 (75 %); m.p.: 204–205 °C; Rf = 0.60 (ethyl-
acetate/n-hexane 1:2); IR (KBr, nmax): 3459, 3316, 3178 (NH2), 3062,
3036 (ArH), 2975 (CH3), 1697(C=O), 1626, 1597 (C=O), 1557,
1496, 1469, 1451 (C=C) cm–1; 1H NMR (DMSO-d6): d 1.32–1.35 (t,
J = 6, 3H, CH2CH3), 4.25–4.30 (q, J = 6.6, 2H, CH2CH3 ), 6.3 (s, 1H,
pyrazole –CH), 7.23–7.63 (m, 13H, ArH and NH2) ppm;
ESI(+)-MS: m/z 442 (M+H)+; Anal. calcd. for C24H19O4N5:
C, 67.44; H, 4.45; N, 16.39 %. Found: C, 67.40; H, 4.51; N, 16.19 %.
4. Antimicrobial Activity
All the novel synthesized compounds 1–12 were screened for
their in vitro antibacterial activity against two Gram-positive
strains, i.e. Bacillus subtilis (NCIM 2439) and Staphylococcus aureus
(NCIM 2079) and two Gram-negative strains, i.e. Escherichia coli
(NCIM 2064) and Pseudomonas aeruginosa (NCIM 2053) in addi-
tion to a fungus Aspergillus niger (NCIM 501). Antibacterial activ-
ity was assessed by serial twofold (broth) dilution technique,
using Muller-Hinton broth for bacteria and Sabouraud dextrose
agar for fungus in the concentration of 1000 µg mL–1. Ampicillin
was used as a standard drug for bacteria and Clotrimazole for
fungus. Similarly, serial dilution tubes for standard drug with its
stock solution 100 µg mL–1 were also prepared so that the concen-
trations of standard drug in five tubes were 50, 25, 12.5, 6,
3 µg mL–1. Antimicrobial activity of dimethyl sulphoxide against
the organisms were investigated, it was nil. Double strength
nutrient broth was used as a growth media. The stock solution
was serially diluted to give concentration of 500–15 µg mL–1 in
nutrient broth. The inoculums size was approximately 106
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colony forming units (CFC mL–1). The inoculated tubes were
incubated for 24 h at 37(±1) °C (bacteria) and for 72 h at 28 °C
(fungus). After 24 h and 72 h the inoculated culture tubes were
macroscopically examined for turbidity. The culture tube
showing turbidity (lower concentration) and culture tube
showing no turbidity (higher concentration) gave the minimum
inhibitory concentration (MIC) for the compound. The
antimicrobial activity of all the screened compounds as well as
standard drug Ampicillin and Clotrimazole determined in terms
of minimum inhibitory concentration (MIC µg mL–1) are given in
Table 1.
5. Conclusions
Methyl4-(benzofuran-2-yl)-2,4-dioxobutanoate 1 was reacted
with various nucleophilic reagents such as hydroxylamine
hydrochloride, semicarbazide hydrochloride, hydrazine
hydrate and phenyl hydrazine to synthesize novel isoxazole and
pyrazole-3-carboxylates derivatives. 5-(benzofuran-2-yl)-1-
phenyl-1H-pyrazole-3-carbohydrazide 6 was further utilized for
the synthesis of newer 1,3,4-oxadiazole and 5-amino pyrazole-
4-carboxylate derivative. The compounds exhibited promising
antibacterial activity in vitro against both Gram-positive and
Gram-negative strains of bacteria along with a fungus.
Acknowledgements
The authors are thankful to the Head, Department of Applied
Chemistry, Priyadarshini College of Engineering, and Nagpur
for providing Laboratory facilities and to the Director, SAIF,
Punjab University, and Chandigarh for providing 1H-NMR,
13C NMR and Mass Spectra, RSIC, CDRI, Lucknow, India for pro-
viding CHN analysis. The authors are also thankful to Dr. Ugale,
Head, Department of Pharmacology, College of Pharmacy,
Kamptee for antimicrobial screening of the compound.
References
1 A.M. Farag, A.S. Mayhoub, S.E. Barakat and A.H. Bayomi, Bioorg.
Med. Chem., 2008, 16, 4569–4578.
2 B. Insuasty, A. Tigreros, F. Orozco, J. Quiroga, R. Abonia, M.
Nogueras, A. Sanchez and J. Cobo, Bioorg. Med. Chem., 2010, 18,
4965–4974.
3 A.M. Farag, A.S. Mayhoub, S.E. Barakat, A.H. Bayomi, Bioorg. Med.
Chem., 2008, 16, 881–889.
4 I. M. El-Deeb and S.H. Lee, Bioorg. Med. Chem., 2010, 18, 3961–3973.
5 B.S. Holla, P.M. Akberali and M.K. Shivananda, IL Farmaco., 2000, 55,
256–263.
6 A. Mustafa, C.A. Hismat and M.M.J. Yannis, J. Prakt. Chem., 1970, 312,
1011–1019.
7 M.H. Elnagdi, M.R.H. Elmoghayor, E.A.A. Hafez, and H.H. Alnima,
J. Org. Chem., 1975, 40, 2604–2607.
8 H.G. Garg, J. Med. Chem., 1972, 15, 446–447.
9 F. Manna, F. Chementi, R. Fioravanti,and A. Bolasco, Bioorg. Med.
Chem. Lett., 2005, 15, 4632–4635.
10 J.H. Ahn, H.M. Kim, S.H. Jung, S.K. Kang, K.R. Kim, S.D. Rhea, S.D.
Yong, H.G. Cheon and S.S. Kim, Bioorg. Med. Chem. Lett., 2004, 14,
4461–4465.
11 R.V. Ragavan, V. Vijayakumar and N.S. Kumari, Eur. J. Med. Chem.,
2010, 45, 1173–1180.
12 Y.R. Prasad, A.L. Rao, L. Prasoona, K. Murali and K.P. Ravi, Bioorg.
Med. Chem. Lett., 2005, 15, 5030–5034.
13 J.C. Jung, E.B. Watkins and M.A. Avery, Heterocycles., 2005, 65, 77–94.
14 A.E. Rashad, M.I. Hegab, R.E. Abdel-Megeid, J.A. Micky and F.M.E.
Abdel-Megeid, Bioorg. Med. Chem., 2008, 16, 7102–7106.
15 M. Ezawa, D.S. Garvey, D.R. Janero, S.P. Khamapure, L.G. Letts,
A. Martino, R.R. Ranetunge, D.J. Schwalb and D.V. Young, Lett. Drug
Design. Discov., 2005, 2, 40–43.
16 B.F. Abdel-Wahab, H.A. Abdel-Aziz and E.M. Ahmed, Arch. Pharm.
Chem. Life Sci., 2008, 341, 734–739.
17 A.R. Farghaly and H. El-Kashef. ARKIVOK, 2006, (xi), 76–90.
18 P. Vicini, F. Zani, P. Cozzini and I. Doytchinova, Eur. J. Med. Chem.,
2002, 37, 553–564.
19 C. Loncle, J.M. Brunel, N. Vidal, M. Dherbomez and Y. Letourneux,
Eur. J. Med. Chem., 2004, 39, 1067–1071.
20 P. Melnyk, V. Leroux, C. Sergheraert and P. Grellier, Bioorg. Med. Chem.
Lett., 2006, 16, 31–35.
21 K. Sridhar, S.N. Pandeya, J.P. Stables and R. Atmakuru, Eur. J. Pharm.
Sci. 2002, 16, 129–132.
22 B.K. Kaymakçloglu and S. Rollas, Il Farmaco., 2002, 57, 595–599.
23 J. Patole, U. Sandbhor , S. Padhye, D.N. Deobagkar, C.E. Anson and
A. Powell, Bioorg. Med. Chem. Lett., 2003, 13, 51–55.
24 E.G. Chalina and L. Chakarova, Eur. J. Med. Chem., 1998, 33(12),
975–983.
25 P.-F. Xu, Z.-H. Zhang, X.-P. Hui, Z.-Y. Zhang, R.-L. Zheng, J. Chin.
Chem. Soc., 2004, 51, 315–319.
26 G. Sahin, E. Palaska, Lu. M. Ekizog, M. Ozalp, Il Farmaco., 2002, 57,
539–542.
27 C.H. Lee, H.I. Cho and K.J. Lee, Bull. Korean Chem. Soc., 2000, 22,
1153–1155.
28 A. Mohsen, M. Omar, and D.A. Wafa, J. Heterocyclic Chem., 1984, 21,
1415–1418.
29 K. Potts, in Comprehensive Heterocyclic Chemistry, (A.R. Katritzky and
C. Rees, eds.), vol. 6, Pergamon Press, Oxford, 1984, p. 427.
30 M. Akhatar, A. Husain, B. Azad and M. Ajaml, Eur. J. Med. Chem., 2009,
44, 2372–2378.
31 A.A. El-Emam, O.A. Al-Deeb, M. Al-Omar and Lehmann, J. Bioorg.
Med. Chem., 2004, 12, 5107–5113.
32 S.G. Küçükgüzel, E.E. Oruc, S. Rollas, F. Sahin and A. Ozbek, Eur. J.
Med. Chem., 2002, 37, 197–206.
33 S.G. Küçükgüzel, A. Kocatepe, E. De Clercq, F. Sahin and M. Güllüce,
Eur. J. Med. Chem. 2006, 41, 353–359.
34 T.M.C. Tan, Y. Chen, K.H. Kong, J. Bai, Y. Li, S.G. Lim, T.H. Ang and
Y. Lam, Antiviral. Res., 2006, 71, 7–14.
35 A.O. Maslat, M. Abussaud, H. Tashtoush and M. Al-Talib, Pol. J.
Pharmacology., 2002, 54, 55–59.
36 J. Taoa, L.H. Cao, C.F. Wang and D.Z. Wang, J. Chin. Chem. Soc., 2006,
53(5), 1193–1197.
37 X. Zheng, Z. Li, Y. Wang, W. Chen, Q. Huang, C. Liu and G. Song,
J. Fluorine. Chem., 2003, 123, 163–169.
38 C.J. Chen, B.-A. Song, S. Yang, G.-F. Xu, P.S. Bhadury, L.-H. Jin, D.-Y.
Hu, Q.-Z. Li, W. Xue, P. Lu and Z. Chen, Bioorg. Med. Chem., 2007, 15,
3981–3989.
39 N.J. Siddiqui, M. Idrees, N.T. Khati and M.G. Dhonde, Bull. Chem. Soc.
Ethio., 2013, 27, 85–94.
RESEARCH ARTICLE N.J. Siddiqui, M. Idrees, N.T. Khati and M.G. Dhonde, 253
S. Afr. J. Chem., 2013, 66, 248–253,
<http://journals.sabinet.co.za/sajchem/>.
